344 related articles for article (PubMed ID: 26023796)
41. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
Sueda T; Sakai D; Kawamoto K; Konno M; Nishida N; Koseki J; Colvin H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Satoh T; Doki Y; Mori M; Ishii H
Sci Rep; 2016 Jan; 6():18949. PubMed ID: 26750638
[TBL] [Abstract][Full Text] [Related]
42. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA
Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948
[TBL] [Abstract][Full Text] [Related]
43. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
[TBL] [Abstract][Full Text] [Related]
44. Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.
Capaldo BJ; Roller D; Axelrod MJ; Koeppel AF; Petricoin EF; Slingluff CL; Weber MJ; Mackey AJ; Gioeli D; Bekiranov S
PLoS One; 2015; 10(9):e0138210. PubMed ID: 26405815
[TBL] [Abstract][Full Text] [Related]
45. Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells.
Ahn JH; Lee YW; Ahn SK; Lee M
Life Sci; 2014 May; 104(1-2):38-46. PubMed ID: 24721513
[TBL] [Abstract][Full Text] [Related]
46. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
Knight DA; Ngiow SF; Li M; Parmenter T; Mok S; Cass A; Haynes NM; Kinross K; Yagita H; Koya RC; Graeber TG; Ribas A; McArthur GA; Smyth MJ
J Clin Invest; 2013 Mar; 123(3):1371-81. PubMed ID: 23454771
[TBL] [Abstract][Full Text] [Related]
47. TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF
Gabler L; Lötsch D; Kirchhofer D; van Schoonhoven S; Schmidt HM; Mayr L; Pirker C; Neumayer K; Dinhof C; Kastler L; Azizi AA; Dorfer C; Czech T; Haberler C; Peyrl A; Kumar R; Slavc I; Spiegl-Kreinecker S; Gojo J; Berger W
Acta Neuropathol Commun; 2019 Aug; 7(1):128. PubMed ID: 31391125
[TBL] [Abstract][Full Text] [Related]
48. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.
Prahallad A; Heynen GJ; Germano G; Willems SM; Evers B; Vecchione L; Gambino V; Lieftink C; Beijersbergen RL; Di Nicolantonio F; Bardelli A; Bernards R
Cell Rep; 2015 Sep; 12(12):1978-85. PubMed ID: 26365186
[TBL] [Abstract][Full Text] [Related]
49. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S
Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020
[TBL] [Abstract][Full Text] [Related]
50. BRAF V600E is a determinant of sensitivity to proteasome inhibitors.
Zecchin D; Boscaro V; Medico E; Barault L; Martini M; Arena S; Cancelliere C; Bartolini A; Crowley EH; Bardelli A; Gallicchio M; Di Nicolantonio F
Mol Cancer Ther; 2013 Dec; 12(12):2950-61. PubMed ID: 24107445
[TBL] [Abstract][Full Text] [Related]
51. GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo.
Zhou X; Shen F; Ma P; Hui H; Pei S; Chen M; Wang Z; Zhou W; Jin B
Mol Med Rep; 2015 Oct; 12(4):5641-6. PubMed ID: 26238593
[TBL] [Abstract][Full Text] [Related]
52. Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.
Fan QW; Specht KM; Zhang C; Goldenberg DD; Shokat KM; Weiss WA
Cancer Res; 2003 Dec; 63(24):8930-8. PubMed ID: 14695210
[TBL] [Abstract][Full Text] [Related]
53. Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines.
Kocher D; Cao L; Guiho R; Langhammer M; Lai YL; Becker P; Hamdi H; Friedel D; Selt F; Vonhören D; Zaman J; Valinciute G; Herter S; Picard D; Rettenmeier J; Maass KK; Pajtler KW; Remke M; von Deimling A; Pusch S; Pfister SM; Oehme I; Jones DTW; Halbach S; Brummer T; Martinez-Barbera JP; Witt O; Milde T; Sigaud R
J Neurooncol; 2024 Jun; 168(2):317-332. PubMed ID: 38630384
[TBL] [Abstract][Full Text] [Related]
54. BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells.
Wu Z; Huang M; Gong Y; Lin C; Guo W
Acta Biochim Biophys Sin (Shanghai); 2018 Apr; 50(4):355-361. PubMed ID: 29534162
[TBL] [Abstract][Full Text] [Related]
55. Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities.
Jonas O; Oudin MJ; Kosciuk T; Whitman M; Gertler FB; Cima MJ; Flaherty KT; Langer R
Clin Cancer Res; 2016 Dec; 22(24):6031-6038. PubMed ID: 27091406
[TBL] [Abstract][Full Text] [Related]
56. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.
Yaeger R; Cercek A; O'Reilly EM; Reidy DL; Kemeny N; Wolinsky T; Capanu M; Gollub MJ; Rosen N; Berger MF; Lacouture ME; Vakiani E; Saltz LB
Clin Cancer Res; 2015 Mar; 21(6):1313-20. PubMed ID: 25589621
[TBL] [Abstract][Full Text] [Related]
57. Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in
Hazar-Rethinam M; Kleyman M; Han GC; Liu D; Ahronian LG; Shahzade HA; Chen L; Parikh AR; Allen JN; Clark JW; Kwak EL; Faris JE; Murphy JE; Hong TS; Van Seventer EE; Nadres B; Hong CB; Gurski JM; Jessop NA; Dias-Santagata D; Iafrate AJ; Van Allen EM; Corcoran RB
Cancer Discov; 2018 Apr; 8(4):417-427. PubMed ID: 29431697
[TBL] [Abstract][Full Text] [Related]
58. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
Silva JM; Bulman C; McMahon M
Mol Cancer Res; 2014 Mar; 12(3):447-63. PubMed ID: 24425783
[TBL] [Abstract][Full Text] [Related]
59. BRAF paradox breakers PLX8394, PLX7904 are more effective against BRAFV600Ε CRC cells compared with the BRAF inhibitor PLX4720 and shown by detailed pathway analysis.
Koumaki K; Kontogianni G; Kosmidou V; Pahitsa F; Kritsi E; Zervou M; Chatziioannou A; Souliotis VL; Papadodima O; Pintzas A
Biochim Biophys Acta Mol Basis Dis; 2021 Apr; 1867(4):166061. PubMed ID: 33385518
[TBL] [Abstract][Full Text] [Related]
60. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
Salerno P; De Falco V; Tamburrino A; Nappi TC; Vecchio G; Schweppe RE; Bollag G; Santoro M; Salvatore G
J Clin Endocrinol Metab; 2010 Jan; 95(1):450-5. PubMed ID: 19880792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]